This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.94% per year. These returns cover a period from January 1, 1988 through June 1, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
biotechs: Archive
Novartis' Rhapsido Meets Primary Goal in Phase III Skin Disorder Study
by Zacks Equity Research
Novartis reports phase III RemIND success for Rhapsido in chronic inducible urticaria, showing higher response rates and supporting new filings.
NVSNegative Net Change BAYRYNegative Net Change IMCRNegative Net Change
biotechnology biotechs medical pharmaceuticals
AstraZeneca's Truqap Wins FDA Nod for Prostate Cancer Indication
by Zacks Equity Research
AZN wins FDA approval to expand Truqap's use in PTEN-deficient prostate cancer, backed by phase III data showing improved outcomes and broader use.
AZNNegative Net Change JNJNegative Net Change LQDANegative Net Change INDVNegative Net Change
biotechs
Can Bristol Myers' Growth Portfolio Offset Legacy Drug Declines?
by Zacks Equity Research
BMY's growth portfolio now drives more than half of revenues, with strong gains from Reblozyl, Breyanzi and Cobenfy helping offset legacy drug declines.
BMYNegative Net Change PFENegative Net Change MRKNegative Net Change
biotechnology biotechs medical pharmaceuticals
Immunovant Stock Gains 12.4% in a Month: What's Driving It?
by Zacks Equity Research
IMVT shares climb as IMVT-1402 posts encouraging data, advances across autoimmune diseases and benefits from a cash runway extending through launch.
LQDANegative Net Change IMVTNegative Net Change IMCRNegative Net Change INDVNegative Net Change
biotechs
Is Indivior Stock a Buy After Higher 2026 Guidance?
by Kinjel Shah
Indivior raised 2026 guidance after strong Q1 results, but investors are watching whether Sublocade growth and margin gains can sustain momentum.
ACIUNegative Net Change LQDANegative Net Change IMCRNegative Net Change INDVNegative Net Change
biotechs
GSK's Momelotinib Gets Orphan Tag for Rare Hemato-Inflammatory Disorder
by Zacks Equity Research
GSK's momelotinib wins FDA and EMA orphan status for VEXAS syndrome, backed by early evidence. The company advances a phase II/III study.
GSKPositive Net Change LQDANegative Net Change IMCRNegative Net Change INDVNegative Net Change
biotechs
IMRX Begins Dosing in Phase III Pancreatic Cancer Study, Stock Up
by Zacks Equity Research
Immuneering stock rises after dosing the first patient in a pivotal phase III study of atebimetinib plus mGnP for first-line metastatic pancreatic cancer.
REGNNegative Net Change LQDANegative Net Change IMCRNegative Net Change IMRXNegative Net Change
biotechs
Can Alnylam Rely on Amvuttra to Sustain Its Rapid Sales Momentum?
by Ahan Chakraborty
Amvuttra's blockbuster growth is reshaping ALNY's revenue mix, and fresh ATTR-CM approvals can unlock an even larger market.
ALNYNegative Net Change PFENegative Net Change BBIONegative Net Change
biotechnology biotechs medical pharmaceuticals
Novo Nordisk Stock Up as UK Wegovy Pill Nod Eclipses Security Breach
by Zacks Equity Research
NVO stock gains 3% as the United Kingdom becomes Europe's first country to approve the daily GLP-1 Wegovy weight-loss pill, overshadowing an IT security breach.
NVOPositive Net Change LQDANegative Net Change IMCRNegative Net Change INDVNegative Net Change
biotechnology biotechs medical pharmaceuticals
Pharma and Biotech M&A Boom Accelerates as Companies Expand Pipelines
by Ekta Bagri
Pharma and biotech dealmaking is surging in 2026 as companies pursue acquisitions to expand pipelines, strengthen portfolios and drive growth.
GSKPositive Net Change NVSNegative Net Change MRKNegative Net Change LLYNegative Net Change GILDNegative Net Change
biotechnology biotechs medical pharmaceuticals